Engineered immune cells take on autoimmune diseases in early trial

This early-stage trial is testing a new treatment called OL-CD19-GDT, which uses specially engineered immune cells (CAR-T cells) from a healthy donor to target and destroy faulty immune cells in people with severe autoimmune diseases like systemic sclerosis and Sjogren's syndrome. The study will enroll 44 adults whose disease has returned or not responded to standard treatments. The main goals are to check the treatment's safety and find the right dose, while also looking at how well it works.